SEAGEN INC (SGEN) Fundamental Analysis & Valuation
NASDAQ:SGEN • US81181C1045
Current stock price
228.74 USD
-0.16 (-0.07%)
At close:
228.95 USD
+0.21 (+0.09%)
After Hours:
This SGEN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SGEN Profitability Analysis
1.1 Basic Checks
- In the past year SGEN has reported negative net income.
- SGEN had a negative operating cash flow in the past year.
1.2 Ratios
- With an excellent Return On Assets value of -20.64%, SGEN belongs to the best of the industry, outperforming 82.06% of the companies in the same industry.
- The Return On Equity of SGEN (-29.41%) is better than 81.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| ROIC | N/A |
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Gross Margin value of 75.39%, SGEN belongs to the best of the industry, outperforming 84.88% of the companies in the same industry.
- In the last couple of years the Gross Margin of SGEN has declined.
- SGEN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
2. SGEN Health Analysis
2.1 Basic Checks
- SGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SGEN has more shares outstanding
- There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- An Altman-Z score of 23.31 indicates that SGEN is not in any danger for bankruptcy at the moment.
- SGEN has a better Altman-Z score (23.31) than 94.68% of its industry peers.
- SGEN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 23.31 |
ROIC/WACCN/A
WACC10.94%
2.3 Liquidity
- SGEN has a Current Ratio of 2.67. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 2.67, SGEN is not doing good in the industry: 73.26% of the companies in the same industry are doing better.
- SGEN has a Quick Ratio of 2.12. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of SGEN (2.12) is worse than 76.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.12 |
3. SGEN Growth Analysis
3.1 Past
- SGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.23%.
- Looking at the last year, SGEN shows a very strong growth in Revenue. The Revenue has grown by 23.40%.
- Measured over the past years, SGEN shows a very strong growth in Revenue. The Revenue has been growing by 32.40% on average per year.
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%
3.2 Future
- The Earnings Per Share is expected to grow by 32.31% on average over the next years. This is a very strong growth
- The Revenue is expected to grow by 26.49% on average over the next years. This is a very strong growth
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. SGEN Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SGEN. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGEN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as SGEN's earnings are expected to grow with 29.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y29.83%
5. SGEN Dividend Analysis
5.1 Amount
- SGEN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SGEN Fundamentals: All Metrics, Ratios and Statistics
228.74
-0.16 (-0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-01 2023-11-01/bmo
Earnings (Next)02-13 2024-02-13/amc
Inst Owners0.21%
Inst Owner Change0%
Ins Owners0.86%
Ins Owner Change0%
Market Cap43.15B
Revenue(TTM)2.30B
Net Income(TTM)-750.20M
Analysts72.17
Price Target233.48 (2.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-39.9%
Min EPS beat(2)-42.41%
Max EPS beat(2)-37.4%
EPS beat(4)1
Avg EPS beat(4)-16.67%
Min EPS beat(4)-42.41%
Max EPS beat(4)24.39%
EPS beat(8)3
Avg EPS beat(8)-5.14%
EPS beat(12)5
Avg EPS beat(12)-16.24%
EPS beat(16)8
Avg EPS beat(16)36.61%
Revenue beat(2)2
Avg Revenue beat(2)2.94%
Min Revenue beat(2)0.14%
Max Revenue beat(2)5.73%
Revenue beat(4)3
Avg Revenue beat(4)3.09%
Min Revenue beat(4)-1.45%
Max Revenue beat(4)7.95%
Revenue beat(8)7
Avg Revenue beat(8)5.12%
Revenue beat(12)10
Avg Revenue beat(12)4.52%
Revenue beat(16)14
Avg Revenue beat(16)12.68%
PT rev (1m)0%
PT rev (3m)1.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-47.4%
EPS NY rev (1m)-17.92%
EPS NY rev (3m)-19.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)101391%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)0.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 18.76 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 16.92 | ||
| P/tB | 20.99 | ||
| EV/EBITDA | N/A |
EPS(TTM)-4.01
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-3.72
FCFYN/A
OCF(TTM)-2.86
OCFYN/A
SpS12.19
BVpS13.52
TBVpS10.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -29.41% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.39% | ||
| FCFM | N/A |
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%
F-Score3
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 219.65% | ||
| Cap/Sales | 7% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.67 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 23.31 |
F-Score3
WACC10.94%
ROIC/WACCN/A
Cap/Depr(3y)115.85%
Cap/Depr(5y)145.31%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%
EBIT growth 1Y-18.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.02%
EBIT Next 3Y33.65%
EBIT Next 5Y31.94%
FCF growth 1Y-758.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1946.21%
OCF growth 3YN/A
OCF growth 5YN/A
SEAGEN INC / SGEN Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SEAGEN INC (SGEN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to SGEN.
What is the valuation status for SGEN stock?
ChartMill assigns a valuation rating of 1 / 10 to SEAGEN INC (SGEN). This can be considered as Overvalued.
What is the profitability of SGEN stock?
SEAGEN INC (SGEN) has a profitability rating of 2 / 10.
How financially healthy is SEAGEN INC?
The financial health rating of SEAGEN INC (SGEN) is 7 / 10.